Parkinson’s is an inherited and progressive disease. The most common cause of this disease is mutations in the leucine-rich repeat kinase 2 gene (LRRK2 or dardaria).
Therefore, all medicines used in the treatment help to combat dardarina. The problem is that the vast majority of these drugs cause side effects or produce unwanted clinical results.
But recent research has found that the active form AdoCbl, present in vitamin B12, can act as an LRRK2 inhibitor, alleviating Parkinson’s disease.
The researchers believe that B12 can be recommended for new treatments.
The research was carried out by the Biofisika Institute, in the Basque Country in partnership with the Polytechnic University of Valencia, in Spain, and was published in the scientific journal Cell Research .
The nutrient acts in the formation of red blood cells in the blood and in the proper functioning of the nervous system. Therefore, consumption of B12 can help prevent heart disease and related to nerves and neurons.
Animal foods (meat, fish, eggs, milk, yogurt, cheese) are the ones that contain the highest concentration of this vitamin.
But this vitamin is sensitive to heat, so the way these foods are prepared can influence the amount of vitamin B12 present.
B12 is an important vitamin for the body. Now, with this new discovery, the nutrient can also be used in the treatment of Parkinson’s, ensuring better quality of life for patients.